PROCEPT BioRobotics Stock (NASDAQ:PRCT)
Previous Close
$80.78
52W Range
$39.48 - $103.81
50D Avg
$87.56
200D Avg
$69.82
Market Cap
$4.42B
Avg Vol (3M)
$810.71K
Beta
1.00
Div Yield
-
PRCT Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FNA | Paragon 28, Inc. |
| OFIX | Orthofix Medical Inc. |
| ITGR | Integer Holdings Corporation |
| LUNG | Pulmonx Corporation |
| NPCE | NeuroPace, Inc. |
| SRDX | Surmodics, Inc. |
| LIVN | LivaNova PLC |
| KIDS | OrthoPediatrics Corp. |
| SGHT | Sight Sciences, Inc. |
| AXGN | AxoGen, Inc. |
| SIBN | SI-BONE, Inc. |
| ESTA | Establishment Labs Holdings Inc. |
| CNMD | CONMED Corporation |
| RXST | RxSight, Inc. |